The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
This is the problem there is never any meat on the bones. As you say is the mobile company testing its staff or doing something else. The fact it only deserved a short one line lacking absolutely the tiniest of detail spoke volumes. And why didn’t it warrant a separate RNS. And 18 pharmacies. What does that mean. Is it one group of pharmacies comprising 18 in total or 18 separate ones comprising a lot more than the said 18. The detail is so sparse it’s like it’s deliberately designed to be that way because if you were given the full SP it probably wouldn’t amount to much. I can’t remember what year cliff edge guy, our oscar starring CEO passed out of RADA but in one of his recent performances I think he said the company was fully funded. Or was he talking about his and fartings bank accounts.
This is a strong buy with prices down here, 2.00 - 2.30p imo.
I appreciate holders being upset with the placing, but it has presented a great opportunity to those sitting on the fence, and a good opportunity for existing holders to average down imo.
The company is clearly growing, and this will continue to grow at pace imo. In the last 5 weeks the company has started to work with 18 pharmacies (confident this number will grow significantly) and a major U.K. mobile operator.
Is the major U.K. mobile operator using CTEA for testing their employees or are they connected to CTEA because of the Tech ? (The RNS does not give a definitive answer)
Do not underestimate how important and the value it adds to the company being awarded ISO 27001 & Cyber Essentials accreditation. ....... this will unlock doors.
Contracts, decent contracts, will soon follow imo.
I am of the opinion this will multibag from here in the next 2- 6 months. Double / treble your money within 6 months imo.
Buy, sell, remain sitting on the fence ........ your choice, but I bought back in today !
This placing shouldn't have come as a surprise as looking at accounts, it was clear cash was running low. 2p placing price is the same as last year so likely to have a rise based on some news within 3-4 weeks. Stochs are oversold and RSI at 39. SP may fall to 1.8p before rising.
No sales, no revenue. Just false hope with occasional acting skills in interviews..
Yes that's fair comment.
Pretty sure a trade is being worked - sp is stuck and L2 not really making sense.
I think the problem is that it doesn't really seem to sell its' tech independently.
I did think that the JV would be a game changer. Access to tests and bolt on app sales seemed like a good move. For whatever reason it doesn't seem to have been working out. Surely if they actually had a sale to a major UK mobile network that would have been RNS'd?
Remember CTEA sells its tech independently of that JV with BHA, as it did with NPH and now a major UK mobile operator plus the other pharmacies. I suspect that lack of ISO accreditation has been a problem, but not any more.
Not so sure.
Quote from company :
'Albeit neither the Badminton England nor the Stone Bailey agreements will generate significant revenues for the Company, it provides a commercial endorsement for Synovate's offering.'
So not even enough to keep one light on?
Have the company ever explained how their charging structure will deliver revenues?
The company is burning cash with very little to show so far.
That needs to change fast.
GL.
I guess one or two on here think CTEA is providing its technology for free given they state the company isn't generating revenue. Idiotic.
RNS tells us more about to land.